JamesMWellsMDMSPH

Pulmonology • Birmingham, AL

Asthma & COPD, Critical Care Medicine, Pleural Disease

Associate Professor

Join to view full profile

Dr. Wells is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wells' full profile

Already have an account?

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Fax+1 205-933-4497

Summary

Dr. James Wells is a pulmonologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital and Birmingham VA Medical Center. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 14 years. He specializes in asthma & copd, critical care medicine, and pleural disease and is experienced in chronic obstructive pulmonary disease and chronic bronchitis. He has more than 100 publications and over 500 citings.

Education & Training

University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2009 - 2012
University of Alabama HospitalResidency, Internal Medicine, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005

Certifications & Licensure

AL State Medical License 2007 - 2025
SC State Medical License 2017 - 2019
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2007 Nov 01
Active, not recruiting
Study of COPD Subgroups and Biomarkers Start of enrollment: 2010 Nov 01
Active, not recruiting
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Start of enrollment: 2018 Oct 29
Completed
Phase 2
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency Start of enrollment: 2019 Apr 08
Completed
Phase 2
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype Start of enrollment: 2020 Jul 24
Completed
Phase 2
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Start of enrollment: 2020 Sep 04
Completed
Phase 2
COVID-19 Study of Safety and Tolerability of Alvelestat Start of enrollment: 2021 Jan 25
Completed
Phase 1, Phase 2
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) Start of enrollment: 2021 Jan 29
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Differential Association of COPD Subtypes With Cardiovascular Events and COPD Exacerbations.
Han-Mo Yang, Min Hyung Ryu, Vincent J Carey, Kendra Young, Gregory L Kinney
Chest. 2024-12-01
5 citations
Protease-armed, Pathogenic Extracellular Vesicles Link Smoking and Chronic Obstructive Pulmonary Disease.
Matthew C Madison, Camilla Margaroli, Kristopher R Genschmer, Derek W Russell, James M Wells
American Journal of Respiratory and Critical Care Medicine. 2023-11-15
Outcome expectancies and resistance self-efficacy mediate the relationship between asthma diagnosis and e-cigarette use among youth and young adults.
Abdullah M M Alanazi, Mohammed M Alqahtani, J Michael Wells, Donald H Lein Jr, Peter S Hendricks
The Journal of Asthma. 2023-06-01